Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025)

Invivyd posted quarterly Non-Current Deferred Tax Liability of $719000.0 for Q4 2025, up 46.14% year-on-year from $492000.0 in Q4 2024, and up 46.14% on a QoQ basis from $492000.0 in Q4 2024.

Invivyd (IVVD) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $719000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 46.14% year-over-year to $719000.0; the trailing twelve-month figure through Dec 2025 stood at $719000.0 (up 46.14% YoY), and the FY2025 full-year result was $719000.0, up 46.14% from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 stood at $719000.0, up from $492000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $719000.0 in Q4 2025 and bottomed at $492000.0 in Q4 2024.
  • The 3-year median for Non-Current Deferred Tax Liability is $699000.0 (2023), against an average of $636666.7.
  • The widest annual swing landed in 2024, when Non-Current Deferred Tax Liability slipped 29.61%; it then jumped 46.14% in 2025.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $699000.0 in 2023, then retreated by 29.61% to $492000.0 in 2024, then jumped by 46.14% to $719000.0 in 2025.
  • The last three Non-Current Deferred Tax Liability figures came in at $719000.0 (Q4 2025), $492000.0 (Q4 2024), and $699000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Invivyd 208.38 Mn -18.31 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 719,000.00
Dec 31, 2025 719,000.00
Dec 31, 2024 492,000.00
Dec 31, 2024 492,000.00
Dec 31, 2023 699,000.00
Dec 31, 2023 699,000.00